Efficacy and safety of mirikizumab in maintenance therapy for ulcerative colitis in difficult-to-treat inflammatory bowel disease: a single-center retrospective study in Japan

February 11, 2026Intestinal ResearchOpen Access

View Full Paper

Ask AI

Bookmark

Share

Key Points

To assess the efficacy and safety of mirikizumab as a maintenance therapy for ulcerative colitis in patients with difficult-to-treat inflammatory bowel disease.
Conducted a single-center retrospective review of patients
Focused on maintenance therapy with mirikizumab
Collected and analyzed real-world treatment data
Demonstrated promising efficacy of mirikizumab in maintaining remission
Highlighted a favorable safety profile among treated patients
Provided supporting data for the use of mirikizumab in difficult-to-treat cases

Single-center study reveals efficacy of mirikizumab in treating ulcerative colitis, suggesting its potential benefits for difficult cases.

The present study demonstrated real-world data regarding maintenance therapy with mirikizumab for UC among patients with DTT-IBD.

No takes yet. Share an insight, caveat, or question.

Mizushima et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share